Survival after treatment of intrahepatic cholangiocarcinoma with transarterial chemoembolization. A systematic review
DOI:
https://doi.org/10.53903/01212095.400Keywords:
Intrahepatic cholangiocarcinoma, Chemoembolization, therapeutic, Survival, Bile duct neoplasmsAbstract
Objective: Review systematically the scientific literature on the implications of transarterial chemoembolization (TACE) in intrahepatic cholangiocarcinoma, considering survival as the main indicator. Materials and methods: PubMed, Embase, Cochrane, and Lilacs were used to identify potentially eligible studies from January 1, 2010 to December 31, 2020, investigating the effect of TACE in patients with intrahepatic cholangiocarcinoma. The primary endpoint was overall survival, and recurrence-free survival was assessed in some studies. Results: 10 studies with 668 patients with transarterial chemoembolization were included. The overall mean survival was between 10.1
and 27.6 months and the 5-year survival were between 16.2 % and 38.4 %. Conclusion: Transarterial chemoembolization decreased mortality and increased overall mean survival, compared with previous studies and with different treatments.
Downloads
References
Edge S, Compton C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
Rizvi S, Khan S, Hallemeier C, et al. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95-111.
Wu L, Tsilimigras D, Paredes A, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(1):1777-87.
Massarweh N, El-Serag H. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.
Burt A, Alves V, Bedossa P, et al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Histopathology. 2018;73(3):369-85.
Florio A, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126(11): 2666-78.
Jeong Y, Shin H, Lee S, et al. Prevalence of clonorchis sinensis infection among residents along 5 major rivers in the Republic of Korea. Korean J Parasitol. 2016; 54(2):215.
Kitphati R, Watanawong O, Wongsaroj T, et al. National program of opisthorchiasis in Thailand; situation and policy strategy. Int J Geoinformatics. 2021;17(2):61-8.
Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA: Cancer J Clinic. 2023;73(2):198-222.
Primrose J, Fox R, Palmer D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(1):663-73.
Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (Prodige 12-accord 18-Unicancer GI): A randomized phase III study. J Clin Oncol. 2019;37(1):658-67.
Zhang X, Chen Q, Kimbrough C, et al. Lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been increasingly adopted by surgeons over time? a national database analysis. J Gastrointest Surg. 2018;22(1):668-75.
Cloyd J, Mizuno T, Kawaguchi Y, et al. Comprehensive complication index validates improved outcomes over time despite increased complexity in 3707 consecutive hepatectomy. Ann Surg. 2020;271(1):724-31.
Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122(1):3838-47.
Our E, Verster A. Access to hepatitis C care for people who inject drugs and people in prisons. Lancet Gastroenterol Hepatol. 2019;4(9):662-3.
Valle J, Wasan H, Palmer D, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med. 2010;362(14):1273-81.
Boehm L, Jayakrishnan T, Miura J, et al. Comparative effectiveness of hepatic arterybased therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213-20.
Shen W, Zhong W, Liu Q, et al. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35(1):2083-91. Rev. Colomb. Radiol. 2025; 36(3): 6483-9 6489
Kiefer M, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498-505.
Hyder O, Marsh J, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(1):3779-86.
Li J, Wang Q, Lei Z, et al. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. The Oncologist. 2015;20(6):640-7.
Wright G, Perkins S, Jones H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol. 2018;25(1):83-90.
Higaki T, Aramaki O, Moriguchi M, et al. Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma. BioScience Trends. 2018;12(1):73-8.
Peng Z, Cao G, Hou Q, et al. The comprehensive analysis of efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: A multiple-center, cohort study. Oncol Res. 2020;28(3):249271.
Luo J, Zheng J, Shi C, et al. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study. Medicine. 2020;99(12):e19276.
Ge Y, Jeong S, Luo G, et al. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: Development of a prognostic nomogram. Hepatobiliary Pancreatic Dis Int. 2020;19(2):138-46.
Shen F, Xie ZH, Xia Y, et al. Progress on surgical treatment of intrahepatic cholangiocarcinoma. Zhonghua Wai Ke Za Zhi. 2019;57(4):241-6.
Benson A, D’Angelica M, Abbott D, et al. Guidelines insights: hepatobiliary cancers, Version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302-10.
Roayaie S, Guarrera J, Michele Q, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am College Surg. 1998;187(4):365-72.
Friman S. Cholangiocarcinoma—current treatment options. Scand J Surg. 2011;100(1):30-4.
Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Internat. 2019;39(1):123-42.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista Colombiana de Radiología
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La Revista Colombiana de Radiología es de acceso abierto y todos sus artículos se encuentran libre y completamente disponibles en línea para todo público sin costo alguno.
Los derechos patrimoniales de autor de los textos y de las imágenes del artículo como han sido transferidos pertenecen a la Asociación Colombiana de Radiología (ACR). Por tanto para su reproducción es necesario solicitar permisos y se debe hacer referencia al artículo de la Revista Colombiana de Radiología en las presentaciones o artículos nuevos donde se incluyan.
| Article metrics | |
|---|---|
| Abstract views | 116 |
| Galley views | 56 |
| PDF Views | 56 |
| HTML views | 0 |
| Other views | 0 |
